Loyal, a clinical-stage animal health company developing longevity drugs for dogs, announced it has raised a $22M million B-2 round from Valor Equity Partners and Collaborative Fund, among others, in addition to its $45M Series B in 2024. This brings total investment in Loyal's to over $150M.